4575 CanBas Co.,Ltd.キャンバスTSE Growth / Pharmaceuticals
0 posts
CanBas Co.,Ltd. stock rose on Nov 20: what happened
It closed at ¥791 on Nov 20 (+¥17.0, +2.20%), ranking #45 among the top gainers of all stocks on the Tokyo Stock Exchange.
Disclosures around that day
- 11/20 16:30第22回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ
- 11/19 17:00第22回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ
- 11/19 12:04CBP501 欧州臨床第3相試験開始承認受領のお知らせ
- 11/19 12:02第22回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ
Changes are calculated from the closing prices this site collects daily; limit-up/down is an estimate based on the daily price limit. Please make your own investment decisions.
CanBas Co.,Ltd. (4575) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
CanBas Co.,Ltd. (4575) Stock Price History
CanBas Co.,Ltd. closed at ¥791 on Nov 20, 2026, +8.1% over 1 month, +0.3% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥108,060 today (+8.1%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −11.9%, while this stock moved +8.1%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥791 | +17 | +2.20% |
| Nov 19 (Thu) | ¥774 | +100 | +14.84% |
| Nov 18 (Wed) | ¥674 | −16 | −2.32% |
| Nov 17 (Tue) | ¥690 | −29 | −4.03% |
| Nov 16 (Mon) | ¥719 | +14 | +1.99% |
| Nov 13 (Fri) | ¥705 | −5 | −0.70% |
| Nov 12 (Thu) | ¥710 | −12 | −1.66% |
| Nov 11 (Wed) | ¥722 | +13 | +1.83% |
| Nov 10 (Tue) | ¥709 | +20 | +2.90% |
| Nov 9 (Mon) | ¥689 | +23 | +3.45% |
If you had invested ¥100,000 3 months ago, it would be worth ¥97,534 today (−2.5%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved −2.5%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥791 | +17 | +2.20% |
| Nov 19 (Thu) | ¥774 | +100 | +14.84% |
| Nov 18 (Wed) | ¥674 | −16 | −2.32% |
| Nov 17 (Tue) | ¥690 | −29 | −4.03% |
| Nov 16 (Mon) | ¥719 | +14 | +1.99% |
| Nov 13 (Fri) | ¥705 | −5 | −0.70% |
| Nov 12 (Thu) | ¥710 | −12 | −1.66% |
| Nov 11 (Wed) | ¥722 | +13 | +1.83% |
| Nov 10 (Tue) | ¥709 | +20 | +2.90% |
| Nov 9 (Mon) | ¥689 | +23 | +3.45% |
If you had invested ¥100,000 6 months ago, it would be worth ¥132,718 today (+32.7%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −5.6%, while this stock moved +32.7%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥791 | +5.6% |
| Oct 2026 | ¥749 | −5.4% |
| Sep 2026 | ¥792 | −10.4% |
| Aug 2026 | ¥884 | +19.9% |
| Jul 2026 | ¥737 | +24.3% |
| Jun 2026 | ¥593 | −2.9% |
| May 2026 | ¥611 | −8.1% |
If you had invested ¥100,000 1 year ago, it would be worth ¥100,253 today (+0.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +13.3%, while this stock moved +0.3%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥791 | +5.6% |
| Oct 2026 | ¥749 | −5.4% |
| Sep 2026 | ¥792 | −10.4% |
| Aug 2026 | ¥884 | +19.9% |
| Jul 2026 | ¥737 | +24.3% |
| Jun 2026 | ¥593 | −2.9% |
| May 2026 | ¥611 | −8.1% |
| Apr 2026 | ¥665 | −6.7% |
| Mar 2026 | ¥713 | −19.1% |
| Feb 2026 | ¥881 | +1.1% |
| Jan 2026 | ¥871 | +8.5% |
| Dec 2025 | ¥803 | −4.2% |
| Nov 2025 | ¥838 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥76,647 today (−23.4%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +67.8%, while this stock moved −23.4%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥791 | −1.5% |
| 2025 | ¥803 | ― |
If you had invested ¥100,000 5 years ago, it would be worth ¥387,745 today (+287.7%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +96.3%, while this stock moved +287.7%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥791 | −1.5% |
| 2025 | ¥803 | ― |
If you had invested ¥100,000 in Oct 2009, it would be worth ¥26,192 today (−73.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +435.1%, while this stock moved −73.8%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥791 | −1.5% |
| 2025 | ¥803 | −10.4% |
| 2024 | ¥896 | −6.7% |
| 2023 | ¥960 | −17.8% |
| 2022 | ¥1,168 | +548.9% |
| 2021 | ¥180 | −60.6% |
| 2020 | ¥457 | −49.5% |
| 2019 | ¥905 | +113.9% |
| 2018 | ¥423 | −45.0% |
| 2017 | ¥769 | +26.5% |
| 2016 | ¥608 | −31.8% |
| 2015 | ¥892 | −35.1% |
| 2014 | ¥1,374 | +54.9% |
| 2013 | ¥887 | +117.4% |
| 2012 | ¥408 | −11.1% |
| 2011 | ¥459 | −39.1% |
| 2010 | ¥754 | −47.3% |
| 2009 | ¥1,432 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Oct 2009). Please check the latest prices before trading.
CanBas Co.,Ltd. (4575) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of CanBas Co.,Ltd. (4575)
Business overview
The company is a drug discovery company working on basic research, early clinical development and late clinical development of anticancer drugs, and has a single pharmaceutical segment. Based on its own drug discovery platform technology (drug discovery engine), it focuses on specific areas and aims to create both technology and products in-house. Its business model differs from companies that bring in compounds under development from outside and out-license them to pharmaceutical companies. It concentrates on R&D using its unique drug discovery approach and builds its development pipeline with multiple candidate compounds obtained through its own drug screening method. It uses outside specialist organizations such as CROs with extensive anticancer drug development experience and a scientific advisory board, and chooses between advancing development itself through late stages or partnering with pharmaceutical companies according to each pipeline's characteristics and its financial strength.
Summarized from the annual securities report (fiscal year ended June 2026) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 9.73x | Above the sector median of 1.86x (No. 74 from the lowest) |
|---|---|---|
| Market cap | ¥15.6 bn | No. 41 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥956 | 2/3 |
|---|---|---|
| 52-week low | ¥532 | 6/10 |
| Current position | 61.1% | Where the low is 0% and the high is 100% (close on 11/20: ¥791) |
| Year to date | -1.5% | No. 21 of 77 in the sector (best first) |
| 1 year | +0.2% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 gainers | 3 times | Latest: 11/20 (No. 45) |
|---|---|---|
| Top 50 losers | 1 times | Latest: 10/1 (No. 35) |
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/20 16:30第22回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ
- 11/19 17:00第22回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ
- 11/19 12:04CBP501 欧州臨床第3相試験開始承認受領のお知らせ
- 11/19 12:02第22回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ
- 11/13 15:40営業外損益の計上に関するお知らせ
- 11/13 15:402027年6月期 第1四半期決算短信〔日本基準〕(非連結)
- 10/30 15:30第三者割当による第22回新株予約権(行使価額修正条項付)、第23回・第24回新株予約権(行使価額修正選択権付)の発行に係る払込完了に関するお知らせ
- 10/23 15:30譲渡制限付株式報酬としての新株式の発行の払込完了に関するお知らせ
- 10/14 17:05第22~24回新株予約権の発行に関する補足ご説明資料
- 10/14 17:05第三者割当による第22回新株予約権(行使価額修正条項付)、第23回・第24回新株予約権(行使価額修正選択権付)の発行に関するお知らせ
Show 3 more
- 10/14 17:05極度方式基本契約の締結に関するお知らせ
- 10/14 17:05調達資金の使途及び支出時期の変更について
- 09/29 15:30譲渡制限付株式報酬としての新株式の発行に関するお知らせ
Filings from the past 12 months (13).
CanBas Co.,Ltd. in Kabutaro's Daily Blog
- Nov 19, 2026 Japan Stock of the Day: On November 19, 2026, the most talked-about Japanese stock online was CanBas <4575>.
Days when Kabutaro's daily blog featured this stock.
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.
Write on the CanBas Co.,Ltd. board
More Japanese stocks in English
- D.Western Therapeutics Institute, Inc.4576
- Daito Pharmaceutical Co.,Ltd.4577
- RaQualia Pharma Inc.4579
- Le Lien Co.,Ltd.457A
- SymBio Pharmaceuticals Limited4582
- Chiome Bioscience Inc.4583
- Kidswell Bio Corporation4584
- Medrx Co.,Ltd.4586
- PeptiDream Inc.4587
- Oncolys BioPharma Inc.4588
- PLAN DO Co.,Ltd.458A
- RIBOMIC Inc.4591